Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

- Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon release. - Monotherapy in patients inadequately controlled with diet and exercise: provides an oral option to lower HbA1c. - Combination therapy with metformin or other antidiabetic agents: adds complementary glucose‑lowering effect.

Adverse reactions reported with linagliptin are generally mild, but serious events can occur and should be monitored.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: sensation of light‑headedness or imbalance. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation. - Severe allergic reactions: including angioedema, urticaria or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions. - Hypoglycaemia (when combined with insulin or sulfonylureas): marked low blood glucose levels.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: use with caution and monitor renal function, although dose adjustment is generally not required. - Hepatic impairment: assess liver function and monitor for signs of hepatic injury. - Cardiovascular disease: evaluate cardiovascular status as patients may have co‑existing conditions. - Pregnancy: safety category is unknown; avoid use unless potential benefit justifies the risk. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose closely. - Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Linagliptin may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin therapy: combined use can increase the risk of hypoglycaemia. - Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may raise linagliptin plasma concentrations. - Rifampicin or other potent enzyme inducers: can reduce linagliptin exposure and diminish glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Sulfonylureas (e.g., glimepiride): monitor for hypoglycaemia and adjust dose if needed. - Diuretics: assess volume status and electrolytes as blood glucose changes may affect fluid balance. - ACE inhibitors or ARBs: observe blood pressure and renal function when used together. - Other DPP‑4 inhibitors: avoid concurrent use to prevent additive effects.